Anabolic steroidAndrogenTestosterone esterInjectable

Testosterone Acetate

Also known as Test Ace · Testosterone acetate

Written by enwyReviewed 15 Jul 20262 sources0 comments

A very short-acting injectable testosterone ester with a two-carbon acetate chain, even shorter than propionate. Once cleaved it is bioidentical testosterone; the tiny ester gives fast onset, quick clearance and a need for daily injection.

01 Overview

Testosterone acetate carries the shortest common ester on testosterone, giving release kinetics slightly faster than propionate. It is uncommon as a finished product and is mostly encountered in non-clinical settings; its behaviour is essentially that of a fast, short testosterone requiring daily or near-daily dosing.

As with every ester, the acetate only sets the release rate — the liberated hormone and therefore the pharmacodynamics are identical to testosterone. Its practical drawbacks are frequent injections and injection-site irritation typical of short esters.

02 Mechanism

Esterases rapidly cleave the acetate ester to free testosterone, which activates the androgen receptor, aromatises to estradiol, and suppresses gonadotropins by negative feedback.

03 Dosing

Tier	Dose	Route	Notes
Common	300–500 mg/wk	IM	Split into daily or every-other-day injections due to the short ester.
Strong	500–700 mg/wk	IM	Higher doses scale side effects proportionally.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Increased lean massDose-dependent gain in fat-free mass, identical to any testosterone form once cleaved.	+3-6 kg over a cycle	Clinical
Increased strengthSupraphysiological testosterone raises maximal strength.		Clinical
Improved libido and moodRaising serum testosterone improves libido and mood.		Clinical

05 Side effects

Effect	Severity	Frequency	Evidence
Injection-site painFrequent injections of a short ester cause local soreness and irritation.	Mild	Common	Observational
Estrogenic effectsGynecomastia and water retention from aromatisation to estradiol.	Moderate	Common at higher doses	Clinical
HPTA suppressionSuppression of LH/FSH, endogenous production and spermatogenesis.	Severe	Universal	Clinical

06 Legal status

United Kingdom

Class C

as of Jan 2026

United States

Schedule III controlled substance

Prescription required; no widely marketed finished product. · as of Jan 2026

07 References

Testosterone dose-response relationships in healthy young menAm J Physiol Endocrinol Metab, 2001

Pharmacokinetics of testosterone estersClinical Pharmacokinetics

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.